Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Bcl-3 regulates TGF β signaling by stabilizing Smad3 during breast cancer pulmonary metastasis

Bcl-3 regulates TGF|[beta]| signaling by stabilizing Smad3 during breast cancer pulmonary metastasis

The Role of TGFBR3 in the Development of Lung Cancer

ZNF8 Orchestrates with Smad3 to Promote Lung Metastasis by Recruiting SMYD3 in Breast Cancer

PDLIM5 Inhibits STUB1-mediated Degradation of SMAD3 and Promotes the Migration and Invasion of Lung Cancer Cells.

Hypoxia-Inducible Factor 1α Regulates the Transforming Growth Factor β1/SMAD Family Member 3 Pathway to Promote Breast Cancer Progression

Silencing of KIF3B Suppresses Breast Cancer Progression by Regulating EMT and Wnt/β-Catenin Signaling

PTBP3 Mediates TGF-β-induced EMT and Metastasis of Lung Adenocarcinoma

Abstract P1-07-18: Loss of Rab1B Promotes Triple-Negative Breast Cancer Metastasis by Activating TGF-β/Smad Signaling

TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways

14-3-3Ζ/tgfβr1 Promotes Tumor Metastasis in Lung Squamous Cell Carcinoma

CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-β Signaling

JAK/STAT3 Signaling is Required for TGF-β-induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Gr-1+Cd11b+Cells Are Responsible For Tumor Promoting Effect Of Tgf-Ss In Breast Cancer Progression

Myeloid-Derived Suppressor Cells Recruited by Chemokine (C-C Motif) Ligand 3 Promote the Progression of Breast Cancer Via Phosphoinositide 3-Kinase-protein Kinase B-Mammalian Target of Rapamycin Signaling

Bcl-3 Promotes Wnt Signaling by Maintaining the Acetylation of Β-Catenin at Lysine 49 in Colorectal Cancer

Smad3 is a Key Nonredundant Mediator of Transforming Growth Factor Β Signaling in Nme Mouse Mammary Epithelial Cells

Smad2 and Smad3 Have Opposing Roles in Breast Cancer Bone Metastasis by Differentially Affecting Tumor Angiogenesis.

Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma

Bcl6 Represses Smad Signaling in Transforming Growth Factor-Beta Resistance